A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results ...

Intermountain Health is now offering a national first-of-its kind expansion of CAR-T Cell Therapy, bringing cutting-edge ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

June 1 marks the final day of Sawyer Wobig’s treatment for B Cell Acute Lymphoblastic Leukemia. Sawyer, age 9, lives in ...

The Jonathan Jaques Children's Cancer Institute at Miller Children's & Women's Hospital was involved in a pivotal Children's Oncology Group study that has reshaped the standard of care for children ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Autolus Therapeutics' autologous CD19-directed CAR T-cell therapy Aucatzyl ...

Huntsman Cancer Institute completed the first successful allogeneic stem cell transplant using cells from a deceased donor.

B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric ...